ULOQ [Study As­sess­ment]

posted by Helmut Homepage – Vienna, Austria, 2017-10-30 10:30 (990 d 04:15 ago) – Posting: # 17947
Views: 6,244

Hi Anand,

» In our Pivotal BE Study ULOQ was observed, whether we should exclude from PK?
» After Dilution also it found ULOQ.
» Method should be redeveloped or revalidated?

Perform a partial validation with a higher dilution. If passing the usual criteria for A&P, re-analyse the sample(s) with high concentrations.

» If included,What justification we should provide to Regulatory Agency?

IMHO, that’s not possible.

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
20,859 posts in 4,361 threads, 1,451 registered users;
online 30 (2 registered, 28 guests [including 15 identified bots]).
Forum time: 15:45 CEST (Europe/Vienna)

The interpretation of facts in a certain way
stimulates other scientists’ thoughts.    Róbert Bárány

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5